Ergomed PLC Company Profile (LON:ERGO)

About Ergomed PLC (LON:ERGO)

Ergomed PLC logoErgomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:ERGO
  • CUSIP: N/A
  • Web:
  • Market Cap: £72.15 million
  • Outstanding Shares: 40,534,000
Average Prices:
  • 50 Day Moving Avg: GBX 181.87
  • 200 Day Moving Avg: GBX 194.27
  • 52 Week Range: GBX 118 - GBX 216.88
  • Trailing P/E Ratio: 254.29
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £45.99 million
  • Price / Sales: 1.57
  • Book Value: GBX 0.88 per share
  • Price / Book: 2.02
  • EBIDTA: £2.55 million
  • Net Margins: -0.72%
  • Return on Equity: -0.92%
  • Return on Assets: -0.59%
  • Average Volume: 15,583 shs.

Frequently Asked Questions for Ergomed PLC (LON:ERGO)

What is Ergomed PLC's stock symbol?

Ergomed PLC trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

How were Ergomed PLC's earnings last quarter?

Ergomed PLC (LON:ERGO) posted its quarterly earnings data on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The company earned $22.91 million during the quarter. Ergomed PLC had a negative return on equity of 0.92% and a negative net margin of 0.72%. View Ergomed PLC's Earnings History.

Where is Ergomed PLC's stock going? Where will Ergomed PLC's stock price be in 2017?

3 analysts have issued 12 month price targets for Ergomed PLC's stock. Their predictions range from GBX 275 to GBX 360. On average, they anticipate Ergomed PLC's share price to reach GBX 313 in the next twelve months. View Analyst Ratings for Ergomed PLC.

Who are some of Ergomed PLC's key competitors?

Who are Ergomed PLC's key executives?

Ergomed PLC's management team includes the folowing people:

  • Dan Weng, Chief Executive Officer, Director
  • Miroslav Reljanovic, Executive Vice Chairman of the Board
  • Stephen A. Stamp, Chief Financial Officer, Director
  • Jan Petracek, Chief Executive Officer of PrimeVigilance
  • Andrew Mackie, Chief Business Officer, Executive Director
  • Danko Dominis, Ergomed Head of Business Development
  • Branka Duvnjak, Ergomed Head of Site Management
  • Terry L. Murdock, President of North America, Executive Director of Global Clinical Operations
  • Chris Wilson, Head of Quality and Regulatory
  • Peter Lutz George, Non-Executive Chairman of the Board

How do I buy Ergomed PLC stock?

Shares of Ergomed PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Ergomed PLC's stock price today?

One share of Ergomed PLC stock can currently be purchased for approximately GBX 178.

MarketBeat Community Rating for Ergomed PLC (LON ERGO)
Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about Ergomed PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ergomed PLC (LON:ERGO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 313

Analysts' Ratings History for Ergomed PLC (LON:ERGO)
DateFirmActionRatingPrice TargetDetails
9/19/2017Numis Securities LtdReiterated RatingBuyGBX 275View Rating Details
5/2/2017Stifel NicolausLower Price TargetBuyGBX 315 -> GBX 304View Rating Details
4/21/2017N+1 SingerBoost Price TargetBuyGBX 293 -> GBX 360View Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Ergomed PLC (LON:ERGO)
Earnings by Quarter for Ergomed PLC (LON:ERGO)
Earnings History by Quarter for Ergomed PLC (LON ERGO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/18/2017S1 2017GBX 1.20GBX 2,291 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ergomed PLC (LON:ERGO)
Current Year EPS Consensus Estimate: $7.80 EPS


Dividend History for Ergomed PLC (LON:ERGO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ergomed PLC (LON:ERGO)
Insider Trades by Quarter for Ergomed PLC (LON:ERGO)
Insider Trades by Quarter for Ergomed PLC (LON:ERGO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Peter GeorgeInsiderBuy100,000GBX 190£190,000
7/20/2015Reljanovic,MiroslavInsiderSell3,958,020GBX 170£6,728,634
(Data available from 1/1/2013 forward)


Headline Trends for Ergomed PLC (LON:ERGO)
Latest Headlines for Ergomed PLC (LON:ERGO)
DateHeadline logoErgomed PLC (ERGO) Receives Buy Rating from Numis Securities Ltd - September 24 at 4:38 PM logoErgomed Half Years Results "Solid" With Revenue Growth Of 31% - September 19 at 4:14 AM logoErgomed PLC (ERGO) Announces Earnings Results - September 18 at 7:18 AM logoErgomed Completes Recruitment For PeproStat Phase IIb Study - London South East (registration) (blog) - July 25 at 5:32 AM logoErgomed Completes Recruitment For PeproStat Phase IIb Study - July 25 at 12:31 AM logoInvestor Meeting - London South East (registration) (blog) - July 6 at 7:38 PM logoPeproStat study passes recruitment mid-point - London South East (registration) (blog) - June 21 at 6:34 PM logoErgomed Hires Weng As CEO As Founder Moves To Executive Vice Chairman - June 16 at 3:39 PM logoErgomed Plc breached its 50 day moving average in a Bearish Manner : ERGO-GB : June 5, 2017 - June 5 at 11:27 AM logoErgomed Plc – Value Analysis (LONDON:ERGO) : May 22, 2017 - May 22 at 4:44 PM logoErgomed Plc breached its 50 day moving average in a Bullish Manner : ERGO-GB : May 19, 2017 - May 19 at 5:03 AM logoErgomed Co-Development Partner Trial Fails To Meet Primary Endpoint - May 3 at 9:15 AM logoErgomed PLC (ERGO) Price Target Cut to GBX 304 - May 2 at 7:26 AM logoN+1 Singer Increases Ergomed PLC (ERGO) Price Target to GBX 360 - April 21 at 12:15 PM logoErgomed PLC (ERGO) Earns "Buy" Rating from Stifel Nicolaus - April 8 at 6:09 PM logoErgomed PLC (ERGO) Receives "Buy" Rating from Numis Securities Ltd - April 4 at 4:24 PM logoErgomed PLC (ERGO) Insider Peter George Buys 100,000 Shares - April 4 at 11:20 AM logoBrexit could cut U.K. access to new drugs: Ergomed - March 29 at 11:32 AM logoErgomed PLC (ERGO) Rating Reiterated by Numis Securities Ltd - March 20 at 12:33 PM logoErgomed PLC (ERGO) Rating Reiterated by Stifel Nicolaus - March 20 at 12:27 PM logoErgomed Revenue Rises In 2016 As Contract Wins Surge - Finance ... - London South East (registration) (blog) - January 17 at 5:44 PM logoErgomed Revenue Rises In 2016 As Contract Wins Surge - January 17 at 5:34 AM logoErgomed welcomes expansion of Sickle Cell Disease study - November 16 at 10:38 PM logoErgomed Signs Co-Development Deal With Sweden's Asarina Pharma - November 1 at 9:12 AM


Social activity is not available for this stock.


Ergomed PLC (ERGO) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff